SUNET harnesses Adtran’s ALM fiber monitoring solution for national backbone network
28.5.2024 15:00:00 EEST | Business Wire | Press release
Adtrantoday announced that the Swedish University Computer Network (SUNET) has deployed its ALM in-service fiber monitoring solution to enhance network resilience and operational efficiency. The technology equips SUNET’s maintenance teams with real-time insight into the quality of its nationwide backbone infrastructure and identifies the precise location of any fiber issues. As Sweden’s research and education (R&E) network, SUNET empowers academics and scientists across the country to access learning resources, conduct research and collaborate internationally. With the deployment of ALM, the Nordics’ R&E community has additional assurance of uninterrupted, high-quality services. NetNordic, a key technology partner of SUNET, was also involved in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528454910/en/
Adtran’s ALM is helping SUNET monitor its national fiber network to rapidly identify faults and support swift resolution. (Photo: Business Wire)
“SUNET is a world-class high-capacity optical transport network connecting over 110 organizations and serving a community of 750,000 students, teachers and researchers across Sweden and beyond. The deployment of our ALM platform, with its passive fiber monitoring capabilities, has built even more resilience into this crucially important infrastructure, rendering services more reliable and streamlining operations,” said Stuart Broome, GM of EMEA sales at Adtran. “Finding the exact location of faults is a huge challenge for any operator. But now, with the ability to monitor the integrity of its fiber plant passively and proactively, SUNET’s maintenance teams no longer have to engage in costly and complicated post-failure analysis. ALM enables them to address issues before they impact the high-bandwidth, low-latency services Sweden’s R&E community relies on.”
The deployment of Adtran’s 16-port ALM fiber assurance solution across SUNET’s extensive fiber 8,000km backbone network enables rapid identification and resolution of failures, enhancing network resilience. This is a crucial advantage for a user community involved in data-heavy scientific research. The technology also helps improve efficiency by enabling proactive maintenance. Through an intuitive graphical user interface, SUNET can leverage ALM to monitor a vast national infrastructure containing RAMAN-amplified optical links. The platform detects abnormal attenuation, fiber breaks, tapping attempts and other issues that have the potential to impact connection quality and service availability. ALM also boosts sustainability by cutting down on truck rolls, while its low power use and fanless design ensure a greener, less resource-heavy network.
“From climate science to engineering to medicine, SUNET supports a wide range of important data-intensive projects. That’s why its infrastructure needs to be both fast and highly reliable. Our ALM technology guarantees peak network efficiency and resilience against unpredictable challenges like excavation damage or severe storms. With 24/7 monitoring capabilities, it enables SUNET’s maintenance teams to quickly identify and rectify any issues, ensuring uninterrupted, high-quality service,” commented Sander Jansen, GM of infrastructure monitoring at Adtran. “Moreover, our technology enhances environmental sustainability by reducing unnecessary site visits and lowering carbon footprint. This creates a network that benefits not just today’s users but also future generations.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About SUNET
SUNET, the Swedish University Computer Network, has served the Swedish universities and other organizations closely related to research and education for more than 40 years. We provide the connected organizations with access to well-developed and effective national and international data communication, a national academic identity infrastructure and other related services that meet their needs, regardless of their geographical location. We are part of the Swedish Research Council and connect Sweden through 8400 km of nationwide dark fiber. For more information, please visit www.sunet.se.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528454910/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
